# XERS earnings call intelligence LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/XERS) · [Earnings tab](https://www.lopjlb.com/stock/XERS?tab=earnings) Updated: 2026-08-06T07:53:23 Quarters analyzed: 8 ## Cross-quarter narrative Across eight quarterly CallCards from Q2 2024 to Q1 2026 Xeris transitioned from raising FY24 revenue guidance to delivering record revenue growth and positive adjusted EBITDA. Early calls highlighted strong demand for all three products, modest expense growth and a cash‑rich balance sheet while flagging generic pressure on Keveyis and seasonal Gvoke dynamics. By Q3 2024 the company raised guidance again, noted healthy margins despite a Gvoke write‑off, and signaled uncertainty around XP‑8121 Phase 3 timing. The 2025‑2026 period showed accelerating commercial expansion—particularly Recorlev—robust gross‑margin improvement (82‑87%), and a clear move of XP‑8121 into pivotal Phase III trials. Guidance consistently climbed, culminating in a 30%+ FY25 outlook and a 2026 target above $375 M. While payer‑reset headwinds emerged for Gvoke, overall revenue momentum, margin expansion, and cash‑flow positivity suggest improving operational execution. Persistent themes include ongoing generic competition for Keveyis, continued XP‑8121 timeline risk, and Recorlev’s reliance on referral pipelines, but earlier cash‑flow concerns have largely resolved. ## Latest CallCard · Q1 Xeris posted a strong Q1 2026 with 43% revenue growth, raised the low end of its full‑year guidance, highlighted Recorlev’s commercial expansion, noted Gvoke payer‑reset headwinds, and said XP‑8121 Phase III is on track. **Guidance:** raised — Bottom end of revenue guidance lifted to $380‑$390 M from $375‑$390 M based on Q1 performance and commercial expansion. **Tone:** mgmt 0.7 · Q&A pressure 0.5 · divergence 0.3 Prepared remarks emphasized an "amazing start" with double‑digit product growth, successful commercial expansion and confidence in pipeline milestones. ### Demand visibility Strong demand for Recorlev driven by record referrals and new patient starts; Gvoke faces temporary payer‑reset headwinds. Recorlev benefited from a surge of new patients in March and an expanded field organization; Gvoke’s demand was softened by Medicare deductible changes affecting out‑of‑pocket costs. ### Margins / costs Gross margin improved to 87% (+2% YoY) while SG&A and R&D rose to support growth. Margin boost came from favorable product‑mix dynamics; SG&A up 21% for Recorlev sales force expansion and R&D up 13% for XP‑8121 development. ### Capital allocation Reinvesting cash into commercial expansion, XP‑8121 and optional debt financing. Focus is on growth‑driving investments; balance‑sheet health provides flexibility for debt or other capital‑structure actions. ### Milestones - **Recorlev commercial expansion** [delivered]: Sales force and patient‑support teams expanded exactly as planned, expected to add incremental revenue in H2. - **XP‑8121 Phase III initiation** [on_track]: Trial start slated for later this year after device and formulation scale‑up and go‑to‑market prep. - **Comprehensive program review (XP‑8121)** [new]: Planned for fall to share additional Phase III design details. - **Gross margin improvement** [on_track]: Margin rose to 87% driven by favorable product mix. ### Fears / risks - **payer/reimbursement risk**: Medicare reset increased deductibles and out‑of‑pocket costs, reducing Gvoke prescription fills. - **competitive risk**: Competitor BAQSIMI’s different channel mix insulated it from the Medicare impact that hit Gvoke harder. - **clinical development risk**: XP‑8121 trial start depends on completing device/formulation scale‑up and a go‑to‑market presentation. - **seasonality risk**: Q1 payer resets and typical winter dynamics created a soft start for Gvoke. - **commercial execution risk**: Recorlev’s expanded sales force may take 6‑9 months to fully drive incremental revenue. ### Key quotes > “Our gross margin for the first quarter was 87%, an increase of 2% versus last year. This improvement was primarily driven by favorable product mix dynamics.” > “We are raising the low end of our total revenue guidance to a range of $380 million to $390 million compared to our prior range of $375 million to $390 million.” ## Quarter one-liners - **2026 Q1:** Xeris posted a strong Q1 2026 with 43% revenue growth, raised the low end of its full‑year guidance, highlighted Recorlev’s commercial expansion, noted Gvoke payer‑reset headwinds, and said XP‑8121 Phase III is on track. - **2025 Q4:** Xeris Biopharma achieved financial self-sustainability in 2025 with 44% revenue growth to $292M and $59M adj. EBITDA; 2026 guidance $375-390M (>30% growth) with doubled Recorlev sales force and XP-8121 Phase III initiation in H2.','tone': {'mgmt': 0.8, 'mgmt_rationale': 'Management described 2025 as - **2025 Q3:** Xeris Q3 revenue $74.4M (+40% YoY), raised FY guidance to $285-290M; RECORLEV doubled to $37M, commercial expansion underway, XP-8121 Phase III H2 2026, first net income achieved.','tone': {'mgmt': 0.8, 'mgmt_rationale': 'Management highlighted record revenue, raised guidance, first net income, and - **2025 Q2:** Xeris Biopharma Q2 2025: revenue up 49% to $71.5M, Recorlev +136% YoY; raised FY25 guidance to $280-290M; accelerating investment in Recorlev and XP-8121 Phase III in 2026. Adjusted EBITDA positive $12.5M. All three products growing. Competitive dynamics in hypercortisolism noted. - **2025 Q1:** Xeris Q1 revenue +48% YoY to $60.1M, raises FY guidance floor to $260M; Recorlev +141% YoY, Gvoke +26%, Keveyis stable; adjusted EBITDA positive $4.4M; XP-8121 update June 3.','tone': {'mgmt': 0.8, 'mgmt_rationale': 'Management highlights record-breaking 48% revenue growth, raises full-year guidance - **2024 Q4:** Xeris Biopharma reports 2024 revenue $203M (+24%), guides 2025 $255-275M (>30% growth), adjusted EBITDA positive, Recorlev 118% growth, Gvoke 24%, Keveyis stable, XP-8121 Phase 3 readiness midyear update.','tone': {'mgmt': 0.8, 'mgmt_rationale': 'Management highlights exceptional execution, transfor - **2024 Q3:** Xeris reported a record Q3 with $54.3M revenue, 27% product growth, raised 2024 revenue guidance to $198‑202M, strong demand for Recorlev and Gvoke, and progress on XP8121 and partner programs. - **2024 Q2:** Xeris raises FY24 revenue guidance to $190-200M after 26% YoY Q2 growth across all three products; new CEO prioritizes commercial growth, financial discipline, and better communications. Cash $77.6M, no dilution planned. XP-8121 Phase 2 positive, FDA meeting this fall. Keveyis resilient despite gene ## Theme arcs - **Revenue growth** (improving): Guidance and actual revenue rose each quarter, reaching $292 M in FY25 - **Guidance trajectory** (improving): Guidance lifted from $190‑200 M FY24 to $375‑390 M FY26 - **Product demand** (improving): Strong demand across Recorlev, Gvoke and Keveyis persisted, though Gvoke faced payer reset headwinds - **Gross margin** (improving): Margin climbed from 82% (Q2 2025) to 87% (Q1 2026) - **Cash efficiency** (improving): Shift from cash‑burn concerns to positive adjusted EBITDA and self‑sustainability - **Commercial execution** (improving): Sales‑force expansions and market‑share gains for Recorlev and Gvoke - **XP‑8121 development** (improving): Progressed from Phase 2 completion to Phase III initiation - **Keveyis competitive risk** (stable): Generic pricing pressure noted throughout - **Gvoke payer risk** (deteriorating): Seasonal flattening and Medicare reset increased reimbursement uncertainty - **Re​corlev growth sustainability** (stable): Reliant on referral conversion and payer processes ## Guidance path 2024 Q2:raised → 2024 Q3:raised → 2024 Q4:vague → 2025 Q1:vague → 2025 Q2:raised → 2025 Q3:vague → 2025 Q4:vague → 2026 Q1:raised --- Research context only. Not personalized investment advice. API: `GET /bff/api/bigfive/earnings-intel/XERS`